The groups say that while they fully support transparency in medicine pricing, they strongly object to the use of the Price Control and Anti-Profiteering (Price Marking for Drugs) Order 2025, under the Price Control and Anti-Profiteering Act 2011 (Act 723).
“Many queries were raised as to...
